Xlife Sciences AG (FRA:XLS) Total Receivables: €0.49 Mil (As of Dec. 2025)


FRA:XLS Xlife Sciences AG FRA:XLS
56 GF Score
Price €21.60
GF Value €7.80
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Total Receivables?

Xlife Sciences AG FRA:XLS -2.70% 56 Total Receivables is €0.49 Mil as of Dec. 2025. GuruFocus rates FRA:XLS with a GF Score™ of 56/100 and a GF Value™ of €7.80 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Xlife Sciences AG's Total Receivables for the quarter that ended in Dec. 2025 was €0.49 Mil.

Xlife Sciences AG Total Receivables Related Terms

Xlife Sciences AG Total Receivables Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Total Receivables Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial 0.50 0.97 18.97 15.02 0.49

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.97 18.51 15.02 13.79 0.49
FRA:XLS
56GF Score
Xlife Sciences AG FRA:XLS
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.49 Mil mean?
Xlife Sciences AG (FRA:XLS) has a Total Receivables of €0.49 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Total Receivables too high?
Xlife Sciences AG's current Total Receivables is €0.49 Mil. Overall, Xlife Sciences AG has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Total Receivables compare to VRTX and REGN?
Xlife Sciences AG's Total Receivables of €0.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Total Receivables is €0.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (FRA:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.80, compared to a current price of €21.60 — trading 176.9% above its estimated fair value. The current Total Receivables is €0.49 Mil. Xlife Sciences AG's overall GF Score™ is 56/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Xlife Sciences AG (FRA:XLS), the current Total Receivables is €0.49 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (FRA:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of €21.60 is trading 176.9% above its estimated GF Value™ of €7.80. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for FRA:XLS:

  • Total Receivables: €0.49 Mil
  • GF Value™: €7.80 vs. price of €21.60 (176.9% above fair value)
  • GF Score™: 56/100 with 10 warning signs

No single metric tells the full story. See the FRA:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Switzerland
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
56GF Score

Get the complete analysis for FRA:XLS

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.60
Price
€7.80
GF Value